PGEN PRECIGEN, INC. Insider Trading

CFO Harry Jr. Thomasian sells 200,000 shares (36.1% of holdings) at blended $5.57; scheduled 10b5-1 plan

Harry Jr. Thomasian, PGEN's CFO, executed 2 separate sales totaling 200,000 (200.0K shares) for $1,113,142.75 ($1.1M) on 2026-06-29 and 2026-07-01 under a pre-arranged 10b5-1 trading plan. The sales reduced his holdings from 554,535 shares (554.5K shares) to 354,535 shares (354.5K shares), representing a -36.1% reduction in his position. Since this transaction is part of a scheduled 10b5-1 plan, it reflects a predetermined trading arrangement rather than discretionary action. The current stock price of $5.25 is -13.1% below the 52-week high of $6.04, and the insider's transaction prices (blended $5.57) were above current price, placing the sales at a premium to today's valuation. Context: the company is unprofitable (net income $-7.9M in latest quarter, full-year negative) despite strong revenue growth of +146.7% annually, which underscores the disconnect between growth and profitability that characterizes the business fundamentals.

PGEN CEO Sabzevari sells 346,836 shares ($2.0M) via scheduled 10b5-1 plan; retains 3.77M shares plus 500,164 options

Helen Sabzevari, President and CEO of Precigen, sold 346,836 shares at $5.89 on June 29, 2026, as part of a pre-arranged 10b5-1 trading plan, reducing her non-derivative holdings from 4.12M to 3.77M shares. This is a scheduled transaction, not a discretionary sale, and her overall position remains substantial when accounting for 500,164 shares in derivative holdings (options to purchase common stock). The sale occurs against the backdrop of mixed fundamentals: the company posted $23.3M in latest-quarter revenue with +146.7% annual growth, but remains unprofitable with a $-7.9M net loss over its most recent full fiscal year. The stock has appreciated 27.4% over 30 days and 33.2% over 90 days from depressed levels, trading 13.1% below its 52-week high of $6.04. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it does not reflect a timing judgment or conviction signal; the pattern should be evaluated as a liquidity or pre-planned compensation event rather than as an affirmative market signal.

Director Kirk Randal J sold 4.77M shares (28.0% of holdings) for $15.8M at $3.30 on 2026-03-30.

Kirk Randal J executed 11 separate sales totaling 4,772,781 shares for $15,750,177.30, reducing his position from 17.04M to 12.26M shares. This represents a substantial 28.0% reduction in holdings in a single trading session. His prior 5 sales at PGEN were executed on 2025-12-22 and all exhibited well-timed patterns with negative 90-day returns (down -21.5% in each case post-sale), reflecting a track record of selling before declines at this ticker. The company operates with significant losses: latest quarter revenue of $1,767,000 against net income of -$146,344,000, and it remains unprofitable on a full-year basis despite reporting annual revenue growth of 146.7%. The director's substantial liquidation following a pattern of historically well-timed PGEN exits merits close attention given the company's challenging profitability profile.

Director Kirk Randal J sells 1,900,036 shares at $4.18 for $7,942,150.48 at PGEN; holdings drop 29.2% in 11 transactions on single day.

Kirk Randal J, a Director at Precigen Inc., executed 11 separate sales totaling 1,900,036 shares for $7,942,150.48 at $4.18 on 2025-12-22, reducing his holdings from 6,498,080 shares to 4,598,044 shares (a -29.2% reduction in his stake). The company is unprofitable with a net income of $-146,344,000.00 and annual revenue growth of -74.1%, creating a context of deteriorating financial performance. His cross-ticker track record shows prior sells had an average 90-day return of +8.2% with a 0% well-timed rate, while his five prior same-ticker sales at PGEN yielded mixed outcomes (only one measurable at 90 days: +13.3%). The multi-tranche structure and substantial dollar magnitude ($7.9M) in a single day warrants tracking against subsequent stock performance to assess whether the timing reflected information asymmetry or coincidence.

Director Kirk Randal J sold 2,966,293 shares (34.8% of holdings) for $12.3M across 3 days at blended avg $4.14, now trading $3.88

Kirk Randal J conducted three separate sales totaling 2,966,293 shares for $12,291,748.11 between November 19–21, 2025, reducing his holdings by 34.8% from 8.52M to 5.55M shares. The sales occurred at declining prices ($4.47, $4.08, $3.83) with a blended average of $4.14, and the stock has since fallen to $3.88 (down 20.8% from its 52-week high). His prior trades at PGEN show a pattern of well-timed sales: the two most recent PGEN sales (September 30 and September 19, 2025) each posted positive 30-day returns (+18.8%, +8.7%), indicating he sold before subsequent declines. Against this backdrop of a 74.1% annual revenue decline, a net income of $-146.3M, and a current unprofitable state, the substantial reduction in a director's ownership stake across a multi-day sequence merits close examination of whether material corporate developments or earnings deterioration prompted the transaction.

COO Shah Rutul R bought 2,000 shares of PGEN at $3.40 amid cluster buy; stock down 27.0% in 30 days despite +104.4% in 90 days.

Shah Rutul R, serving as Chief Operating Officer, purchased 2,000 shares at $3.40, increasing his holdings to 405,959 shares post-transaction. This purchase is noteworthy as part of a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated confidence from the leadership group. However, the broader context raises questions about conviction timing: the stock has declined 27.0% over the past 30 days and trades at -30.9% from its 52-week high of $4.76, despite a strong 90-day gain of +104.4%. The company faces significant headwinds—Revenue $1,767,000.00 in the latest quarter, annual revenue growth of -74.1%, and net income of $-26,642,000.00 for the most recent full fiscal year—creating a disconnect between insider buying and fundamental deterioration. The cluster pattern warrants monitoring to determine whether multiple executives are committing additional capital based on non-public information or whether this represents opportunistic accumulation during volatility.

Director Kirk Randal J sold 1,809,667 shares of PGEN at $3.41 on 2025-09-30 for $6.2M, reducing stake 11.0% amid -74.1% annual revenue decline and ongoing losses.

Kirk Randal J sold 1,809,667 shares at $3.41 on 2025-09-30, liquidating 11.0% of his PGEN holdings for $6,170,964.47 while retaining 14.60M shares. This sale follows two other PGEN sells in mid-September and occurs against a backdrop of severe operational deterioration: the company reported -74.1% annual revenue decline and a full-year net loss of -$26,642,000.00, with latest quarterly revenue at only $1,767,000.00. The stock has declined 30.9% from its 52-week high and 27.0% over the past 30 days. Across his prior PGEN trades, the insider showed 2 of 3 measurable outcomes well-timed at the 90-day mark—including his buy on 2024-08-09 returning 11.9% and his buy on 2023-12-28 returning 2.8%—but his cross-ticker track record shows 33.33% 90-day win rate with average 90-day return of -23.7% on prior buys. The confluence of severe revenue contraction, persistent unprofitability, repeated September sales, and stock price deterioration suggests a director reassessment of the company's near-term trajectory.

CCO Tennant Phil buys 6,000 PGEN shares at $3.58; 2 other insiders also bought in past 14 days amid -74.1% revenue decline.

Phil Tennant, Chief Commercial Officer, purchased 6,000 shares at $3.58 on 2025-09-29, increasing his holdings by 10.2% to 65,031 shares total. This transaction is part of a cluster pattern in which 2 other insiders also bought within the past 14 days, suggesting coordinated or at least non-isolated confidence at current prices. However, the broader context raises caution: PRECIGEN reported quarterly revenue of $1.8M (down -74.1% year-over-year), full-year net losses of $-26.6M, and the stock has retreated -27.0% in the past 30 days and stands -30.9% below its 52-week high of $4.76. The cluster buy occurs against deteriorating financial fundamentals and recent downward price momentum, which may reflect opportunistic positioning rather than a return to growth.

CFO Thomasian buys 11,216 shares across 2 transactions (~$40.0K) at blended $3.57 amid 30-day decline of -23.5% and company-wide losses.

CFO Harry Thomasian Jr. executed 2 separate purchases totaling 11,216 shares for $40,015.52 at an average price of $3.57 per share on consecutive dates (2025-09-25 and 2025-09-26). This purchase occurred as the stock declined 23.5% over the preceding 30 days and now trades 26.3% below its 52-week high of $4.76. The company is unprofitable with a net loss of $26,642,000.00 in its most recent full fiscal year and reported a revenue decline of -74.1% year-over-year in the latest quarter (revenue $1.8M). The insider's post-transaction holdings of 468,626 shares represent a 2.5% increase relative to pre-transaction holdings of 457,410 shares. This acquisition by the CFO of a cash-burning company with deteriorating fundamentals—during a period of significant negative price momentum—requires close scrutiny of the company's strategic position and cash runway.

Director Kirk Randal J sells 5,000,252 shares at blended $3.73 for $18.7M; stake reduced 37.0% to 8.52M shares

Kirk Randal J executed two separate sales totaling 5,000,252 shares on 2025-09-18 and 2025-09-19, reducing his stake by 37.0% from 13.52M to 8.52M shares and raising $18,653,532.16. The sales occurred near the 52-week high (current price $3.75 is -21.2% from $4.76 peak), within the stock's 30-day +16.8% and 90-day +158.6% rally. PGEN faces severe operational headwinds: revenue contracted 74.1% year-over-year to $1,767,000 in the latest quarter, the company posted a $26,642,000 net loss, and remains unprofitable on a full-year basis despite a $1.1B market cap—a significant valuation disconnect. Director's prior trades at PGEN show mixed timing outcomes (2 of 5 prior buys yielded positive 90-day returns), though his cross-ticker track record is notably weak (33.33% win rate, -23.7% average 90-day return on buys). This large, material reduction in directorial stake amid a period of relative stock strength and deteriorating fundamentals warrants investor attention.